MicroPolicyStudent Spotlight30th September 2026
As Britain races to expand its electricity grid, Ofgem's new commitment fees should thin out a crowded connections queue, but only if they test whether projects are progressing rather than how deep developers' pockets are.
Thomas Clarke11 min read
Student SpotlightMacro23rd September 2026
Trump's promised $5,000 dividend has no confirmed funding source, raising questions about its inflation and economic risks. Here's what the numbers say.
Ranulf Kirby10 min read
Markets2nd August 2026
Sainsbury's got most of its money back from Argos, and the integration did roughly what management said it would. The problem is what the capital earned in the meantime: Argos now makes a 0.2% margin.
Gaurav Bohra10 min read
MarketsGlobal Healthcare2nd August 2026
Big Pharma is acquiring earlier and accepting greater scientific risk for unproven drugs. The driver is not confidence in the science but the fear of a rival securing the next blockbuster first, as a $300bn patent cliff bears down on the industry.
Abdul Wasey Bhatti8 min read
MarketsGlobal Healthcare16th July 2026
A $200 million upfront payment, with milestones potentially taking the deal's total value to $1.9 billion, gives AstraZeneca exclusive rights to develop and commercialise an experimental COPD treatment outside China. More importantly, it highlights a broader shift in how Big Pharma is sourcing innovation.
Abdul Wasey Bhatti4 min read
Macro15th July 2026
China's factories are shipping more than they have in years, driven by an AI-fuelled tech boom. Yet second-quarter growth still slowed to 4.3%, its weakest in decades outside the pandemic, a reminder that strong exports don't always mean a strong economy.
Raghu Kohli6 min read
The Bank of Japan has raised its policy rate five times since 2024, yet the yen just hit a forty year low. Here is what two years of tightening have actually changed, and what is likely to happen next.
Rohan Talwar13 min read
MarketsPrivate Equity6th July 2026
A £5.7bn approach for DCC is as much a bet on the Irish conglomerate's years-long transformation into an energy distributor as it is a straightforward take-private deal, and it says as much about KKR's ambitions as it does about DCC itself.
Sonal Weerasekera7 min read
MarketsGlobal Healthcare3rd July 2026
As NHS waiting lists for autism assessments pass 200,000, private capital is flowing into neurodiversity services – forcing the question of whether profit and patient care can ever be aligned.
Abdul Wasey Bhatti8 min read
MarketsGlobal Healthcare26th June 2026
A single FDA reversal sent Regenxbio's shares soaring and reignited optimism across gene therapy - but one favourable decision cannot solve the commercial challenges that pushed the industry into crisis.
Abdul Wasey Bhatti6 min read
The DOJ says criminal charges are now on the table for firms that use algorithms to coordinate prices. The question at the heart of the case is whether software can produce cartel-like outcomes without anyone picking up a phone.
Jay Patel10 min read
Peace on the warfront provides an opening to sift through the rubble and take account of the damage done so far.
Martim Domingos9 min read